RT Journal Article
T1 Perioperative chemotherapy versus surgery alone for resectable colorectal liver metastases: an international multicentre propensity score matched analysis on long-term outcomes according to established prognostic risk scores
A1 Di Martino, Marcello
A1 Primavesi, Florian
A1 Syn, Nicholas
A1 Dorcaratto, Dimitri
A1 de la Hoz Rodriguez, Angela
A1 Dupre, Aurelien
A1 Piardi, Tullio
A1 Rhaiem, Rami
A1 Blanco Fernandez, Gerardo
A1 Prada Villaverde, Arancha
A1 Rodriguez Sanjuan, Juan C.
A1 Fernandez Santiago, Roberto
A1 Fernandez-Moreno, Maria-Carmen
A1 Ferret, Georgina
A1 Lopez Ben, Santiago
A1 Suarez Munoz, Miguel A.
A1 Perez-Alonso, Alejandro J.
A1 Koh, Ye-Xin
A1 Jones, Robert
A1 Martin-Perez, Elena
K1 Neoadjuvant chemotherapy
K1 Adjuvant chemotherapy
K1 Resection
K1 Cancer
K1 Survival
K1 Proposal
K1 Folfox4
K1 Trials
K1 System
AB Background: There is still uncertainty regarding the role of perioperative chemotherapy (CTx) in patients with resectable colorectal liver metastases (CRLM), especially in those with a low-risk of recurrence.Methods: Multicentre retrospective analysis of patients with CRLM undergoing liver resection between 2010-2015. Patients were divided into two groups according to whether they received perioperative CTx or not and were compared using propensity score matching (PSM) analysis. Then, they were stratified according to prognostic risk scores, including: Clinical Risk Score (CRS), Tumour Burden Score (TBS) and Genetic And Morphological Evaluation (GAME) score.Results: The study included 967 patients with a median follow-up of 68 months. After PSM analysis, patients with perioperative CTx presented prolonged overall survival (OS) in comparison with the surgery alone group (82.8 vs 52.5 months, p = 0.017). On multivariable analysis perioperative CTx was an independent predictor of increased OS (HR 0.705, 95%CI 0.705-0.516, p = 0.029). The benefits of perioperative CTx on survival were confirmed in patients with CRS and TBS scores
PB Elsevier sci ltd
SN 1365-182X
YR 2021
FD 2021-12-08
LK https://hdl.handle.net/10668/26483
UL https://hdl.handle.net/10668/26483
LA en
DS RISalud
RD Apr 17, 2025